Tag Archives: GW Pharmaceuticals

Top 5 States for Marijuana Stocks

Top 5 States for Marijuana Stocks

Top 5 States for Marijuana Stocks

Over the next five years, the U.S. marijuana market could be worth tens of billions of dollars, and according to GreenWave Advisors, LLC, these five states could move the needle most for marijuana companies. Learn just how big the marijuana market may be in California, Washington, Pennsylvania, Colorado, and Michigan in 2021.

Top 3 Most Attractive Investment Subsets Of The Cannabis Industry

Top 3 Most Attractive Investment Subsets of the Cannabis Industry

The cannabis industry is expected to reach $50 billion in size by 2026, according to Cowen & Co., making it one of the fastest growing industries in the world. Investors have taken a growing interest in the industry as legalization has spread across North America. Here are three subsets of the cannabis industry that investors may want to consider for the best risk-adjusted returns.

GWPH Phase 3 Results

GW Pharmaceuticals Achieves Positive Results in Phase 2 Proof of Concept Study in Glioma

LONDON, Feb. 7, 2017 /Weed Wire/ — GW Pharmaceuticals plc (Nasdaq:GWPH) (“GW,” “the Company” or “the Group”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, today announced positive top-line results from an exploratory Phase 2 placebo-controlled clinical study.

How Big Is the Opportunity for Marijuana Stocks in Florida?

How Big Is the Opportunity for Marijuana Stocks in Florida?

Florida is undeniably behind the curve when it comes to passing pro-pot legislation, but the Sunshine State did make up some ground in November, when voters legalized medical marijuana in the state. How big could the medical marijuana market be in Florida for marijuana stocks?

5 Pot Stocks to Watch Now

5 Pot Stocks to Watch Now

Forward-thinking investors are already plotting seven-figure weed windfalls with the top pot stocks from every ecosystem. You see, there’s more to the marijuana industry than just selling cannabis. There are a lot of ways to profit from legal recreational and medical marijuana sales.

'Cannabis in Parkinson's Disease: Growing Like a Weed!'

‘Cannabis in Parkinson’s Disease: Growing Like a Weed!’

“Cannabis in Parkinson’s Disease: Growing Like a Weed!” was presented at the University of Colorado School of Medicine’s Neurology Grand Rounds on Jan. 18, 2017.

How Big Could the Opportunity Be for Marijuana Stocks in California?

How Big Could the Opportunity Be for Marijuana Stocks in California?

The market for marijuana is exploding as Americans overwhelmingly embrace legalization. Analysts are projecting tens of billions of dollars in future marijuana sales, making this an intriguing market for investors.

4 Best Marijuana Stocks to Play the Green Rush

4 Best Marijuana Stocks to Play the Green Rush

Marijuana sales has the potential to greatly add to government’s treasury as well, and it will be immensely helpful in medical fields. Nowadays, it is also easier for banks for provide services for legal marijuana businesses.

Top Marijuana Stocks to Watch in 2017

Top Marijuana Stocks to Watch in 2017

Sales in the legal marijuana industry are skyrocketing, which is why Money Morning created a list of the top marijuana stocks to watch in 2017. But because marijuana is still illegal under federal law, and many of the marijuana stocks on the market are so volatile, this isn’t a list of recommendations. Rather, it’s a list of marijuana stocks they are watching closely in 2017.

Vitality Biopharma: A Seriously Undervalued Cannabis Stock

Vitality Biopharma: A Seriously Undervalued Cannabis Stock

While many investors were drawn in by the myth that millions would be made by investing in the companies that purportedly planned to cultivate and sell medical and leisure based marijuana, they should have been focused on investing in companies that are intent on utilizing the plant’s cannabinoid properties, which are consistently demonstrating extraordinary benefit in treating a host of medical conditions.

4 Stocks You Can Buy to Profit From the Rising Use of MMJ

4 Stocks You Can Buy to Profit From the Rising Use of MMJ

According to a report by the equity research firm Cowen & Co., marijuana will generate $50 billion in revenue by 2026. That’s roughly eight times the estimated revenue this year. GW Pharmaceuticals and Insys Therapeutics are two big companies with an even bigger future.

GWPH Phase 3 Results

GW Announces New Epidiolex® (CBD) Positive Phase 3 Data in Dravet Syndrome and Lennox-Gastaut Syndrome

LONDON, Dec. 5, 2016 /Weed Wire/ — GW Pharmaceuticals plc (Nasdaq:GWPH) (“GW” or “the Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced additional positive Epidiolex® (cannabidiol or CBD) Phase 3 data in poster presentations at the 70th Annual Meeting of the American Epilepsy Society.

Cannabis & Parkinson's Disease Study Preps for Launch

Cannabis & Parkinson’s Disease Study Preps for Launch

On Oct. 2, 2016, Maureen Leehey, MD, discussed the potential of cannabis in treating Parkinson’s disease at the 3rd Annual Parkinson’s Disease Symposium at the University of Colorado Movement Disorders Center.

GWPH Riding High: Stock Rises on Clinical Trial's Positive Results

GWPH Riding High: Stock Rising on Clinical Trial’s Positive Results

On Sept. 26, 2016, GW Pharmaceuticals (Nasdaq:GWPH), a biopharma company with two promising cannabis-based medications, announced positive results for its third study in the United States on the efficacy of Epidiolex, its experimental CBD-based drug, in treating seizures associated with Lennox-Gastaut syndrome.

Third win for cannabis drug in epilepsy sends GW to record high

Third Win for Cannabis Drug in Epilepsy Sends GW to Record High

An experimental cannabis-derived drug has successfully treated children with severe epilepsy in a third late-stage clinical trial, sending shares in Britain’s GW Pharmaceuticals to a record high on Monday.

GWPH Phase 3 Results

GW Pharmaceuticals Announces Second Positive Phase 3 Pivotal Trial for Epidiolex® (cannabidiol) in the Treatment of Lennox-Gastaut Syndrome

LONDON, Sept. 26, 2016 /Weed Wire/ — GW Pharmaceuticals plc (Nasdaq:GWPH) (AIM:GWP) announces positive results of the second randomized, double-blind, placebo-controlled Phase 3 clinical trial of its investigational medicine Epidiolex.

Exclusive: GW Pharmaceuticals Hires Investment Bank Following Approaches - Sources

Exclusive: GW Pharmaceuticals Hires Investment Bank Following Approaches – Sources

GW Pharmaceuticals Plc (Nasdaq:GWPH), a developer of marijuana-based epilepsy treatments, is working with an investment bank after other drugmakers approached it to express interest in an acquisition, people familiar with the matter said.

GWPH Phase 3 Results

GW Pharmaceuticals plc Reports Third Quarter 2016 Financial Results and Operational Progress

LONDON, Aug. 9, 2016 /Weed Wire/ — GW Pharmaceuticals plc (NASDAQ:GWPH) (AIM:GWP) (GW, the Company or the Group), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced financial results for the third quarter ended 30 June 2016.

GWPH Phase 3 Results

GW Pharmaceuticals plc Announces the Closing of U.S. Public Offering of American Depositary Shares (ADSs) Raising $289.8 Million on the NASDAQ Global Market and Full Exercise of Underwriter’s Option to Purchase Additional ADSs

LONDON, July 18, 2016 /Weed Wire/ — GW Pharmaceuticals plc (Nasdaq:GWPH) (AIM:GWP) a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced today the closing of the previously announced offering on the NASDAQ Global Market.

Georgia’s Medical Marijuana Law Just Turned One Year Old

Georgia’s Medical Marijuana Law Just Turned One Year Old

The phones at the Georgia Department of Public Health no longer ring off the hook with people calling to find doctors or asking questions about how the state’s medical marijuana registry works.

GWPH Phase 3 Results

GW Pharmaceuticals Announces Positive Phase 3 Pivotal Trial Results for Epidiolex® (cannabidiol) in the Treatment of Lennox-Gastaut Syndrome

LONDON, June 27, 2016 /Weed Wire/ — GW Pharmaceuticals plc (Nasdaq:GWPH) (AIM:GWP) (“GW,” “the Company” or “the Group”) announces positive results of the first randomized, double-blind, placebo-controlled Phase 3 clinical trial of its investigational medicine Epidiolex® (cannabidiol or CBD) for the treatment of Lennox-Gastaut syndrome (LGS), a rare and severe form of childhood-onset epilepsy.

GWPH Phase 3 Results

GW Pharmaceuticals Announces New Planned Epidiolex (Cannabidiol or CBD) Development Program in Infantile Spasms (IS)

LONDON, June 21, 2016 /Weed Wire/ — GW Pharmaceuticals plc (Nasdaq: GWPH) (AIM: GWP) (“GW” or “the Company”) today announced that the Company has selected infantile spasms (IS) as the fourth target indication for its Epidiolex orphan pediatric epilepsy development program.

GWPH Phase 3 Results

GW Pharmaceuticals to Present at the Goldman Sachs 37th Annual Global Healthcare Conference and the Jefferies 2016 Healthcare Conference

LONDON, May 31, 2016 /Weed Wire/ — GW Pharmaceuticals plc (Nasdaq:GWPH) (AIM:GWP) today announced that Justin Gover, GW’s Chief Executive Officer, is scheduled to present at the Goldman Sachs 37th Annual Global Healthcare Conference.

GWPH Phase 3 Results

GW Pharmaceuticals to Present at the 2016 UBS Global Healthcare Conference on 24 May

LONDON, May 16, 2016 /Weed Wire/ — GW Pharmaceuticals plc (Nasdaq:GWPH), (AIM:GWP), (“GW” or “the Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, today announced that Justin Gover, GW’s Chief Executive Officer, will present at the 2016 UBS Global Healthcare Conference on Tuesday, May 24, 2016, at 8:00 a.m. (EDT) at the Grand Hyatt Hotel in New York City.

GWPH Phase 3 Results

GW Pharmaceuticals plc Reports Second Quarter and Half-Year 2016 Financial Results and Operational Progress

LONDON, May 5, 2016 /Weed Wire/ — GW Pharmaceuticals plc (NASDAQ:GWPH) (AIM:GWP) (AIM:GW) (the Company or the Group), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced financial results for the second quarter and half-year ended 31 March 2016.

GWPH Phase 3 Results

GW Pharmaceuticals to Present at the Bank of America Merrill Lynch 2016 Healthcare Conference on 10 May

LONDON, May 4, 2016 /Weed Wire/ — GW Pharmaceuticals announced that Justin Gover, GW’s Chief Executive Officer, will present at the Bank of America Merrill Lynch 2016 Healthcare Conference on Tuesday, May 10, 2016, at 9:20 a.m. (PDT) at the Encore at the Wynn Las Vegas, Las Vegas, Nev.

Epidiolex in Utah

Epidiolex in Utah: Decrease in Seizure Frequency and Severity

In September 2014, The University of Utah’s Division of Pediatric Neurology and Primary Children’s Medical Center started the first of three clinical trials on the efficacy of Epidiolex, a nonpsychoactive cannabidiol-based drug from GW Pharmaceuticals (NASDAQ: GWPH).

GWPH Phase 3 Results

GW Pharmaceuticals Initiates Phase 3 Pivotal Study in Tuberous Sclerosis Complex

LONDON, April 11, 2016 /Weed Wire/ — GW Pharmaceuticals plc today announced that it has commenced a Phase 3 clinical trial of Epidiolex® (cannabidiol or CBD) as an adjunctive therapy for the treatment of seizures associated with Tuberous Sclerosis Complex (TSC), a rare genetic disorder, the most common symptom of which is epilepsy.

GW Pharma

GW Pharma Reports Positive Results and Stock More than Doubles by Mid-Day

On March 14, 2016, GW Pharmaceuticals (NASDAQ: GWPH), a biopharma company with two promising cannabis-based medications, announced positive results for the first pivotal Phase 3 study of Epidiolex, a CBD-based medicine, in treating Dravet syndrome, a severe form of pediatric epilepsy.

Australia

Australia Takes Steps Toward Medical Cannabis

Ninety-one percent of Australians reportedly favor legalization of marijuana for medical purposes. The strongest support comes from the over-50 set. In December, the federal government created a nationally-consistent licensing scheme to regulate the cultivation of cannabis for medicinal and scientific purposes.

Charlotte's Web

Charlotte’s Web Cannabis Oil Goes on Sale in UK

While it is a far cry from rolling back prohibition altogether, the legalization wave appears to be crashing upon the beaches of the British Isles this summer. As of July 31, 2015, the branded “Charlotte’s Web” CBD oil went on sale in England after it was legalized last month.


Page 1 of 212
Top